
[Federal Register Volume 80, Number 141 (Thursday, July 23, 2015)]
[Notices]
[Page 43782]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18024]



[[Page 43782]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-D-0369]


Product-Specific Bioequivalence Recommendations; Draft and 
Revised Draft Guidances for Industry; Availability; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register of June 30, 2015 (80 FR 37273). 
The document announced the availability of additional draft and revised 
draft product-specific bioequivalence (BE) recommendations. The 
document was published with an incorrect table title and contents. This 
document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy and 
Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.

SUPPLEMENTARY INFORMATION: In FR Doc. 2015-16013, appearing in the 
Federal Register of Tuesday, June 30, 2015, the following corrections 
are made:
    1. On page 37274, in the first column, the title of table 2, 
``Table 2. Revised Draft Product-Specific BE Recommendations for Drug 
Products Cholestyramine'' is corrected to read ``Table 2. Revised Draft 
Product-Specific BE Recommendations for Drug Products''.
    2. On page 37274, in the first column, in the first line of the 
table under table 2, ``Cholestyramine'' is added to precede 
``Doxycycline hyclate, Prasugrel hydrochloride, Tiagabine 
hydrochloride''.

    Dated: July 17, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-18024 Filed 7-22-15; 8:45 am]
 BILLING CODE 4164-01-P


